My NCBISign In

Display Settings:

Format

Send to:

Choose Destination

    Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5228-33. Epub 2001 Apr 17.

    Anti-mosquito midgut antibodies block development of Plasmodium falciparum and Plasmodium vivax in multiple species of Anopheles mosquitoes and reduce vector fecundity and survivorship.

    Lal AA, Patterson PS, Sacci JB, Vaughan JA, Paul C, Collins WE, Wirtz RA, Azad AF.

    Division of Parasitic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Mail Stop 12, 4770 Buford Highway, Chamblee, GA 30341, USA. aal1@cdc.gov

    The mosquito midgut plays a central role in the sporogonic development of malaria parasites. We have found that polyclonal sera, produced against mosquito midguts, blocked the passage of Plasmodium falciparum ookinetes across the midgut, leading to a significant reduction of infections in mosquitoes. Anti-midgut mAbs were produced that display broad-spectrum activity, blocking parasite development of both P. falciparum and Plasmodium vivax parasites in five different species of mosquitoes. In addition to their parasite transmission-blocking activity, these mAbs also reduced mosquito survivorship and fecundity. These results reveal that mosquito midgut-based antibodies have the potential to reduce malaria transmission in a synergistic manner by lowering both vector competence, through transmission-blocking effects on parasite development, and vector abundance, by decreasing mosquito survivorship and egg laying capacity. Because the intervention can block transmission of different malaria parasite species in various species of mosquitoes, vaccines against such midgut receptors may block malaria transmission worldwide.

    PMID: 11309510 [PubMed - indexed for MEDLINE]

    PMCID: PMC33192

    Supplemental Content

    Click here to read Click here to read
    Write to the Help Desk